Elevated levels of pre-procedural high-sensitivity C-reactive protein is associated with midterm restenosis after extra- and intracranial stenting

Journal of Neuroimaging

Volumn 20, Issue 1, 2010, Pages 74-77

  Gupta, Rishi ^a,b   Bhatt, Archit ^a   Kassab, Mounzer ^a   Majid, Arshad ^a  

^a East Lansing   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

C reactive protein; Re stenosis; Stents

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL DIAMETER; CAROTID ARTERY OBSTRUCTION; DRUG ELUTING STENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RESTENOSIS; RISK FACTOR; STENT; BLOOD; BRAIN ANGIOGRAPHY; CAROTID STENOSIS; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; INTRACRANIAL ARTERIOSCLEROSIS; PATHOLOGY; RETROSPECTIVE STUDY; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; UNITED STATES; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; AGED; C-REACTIVE PROTEIN; CAROTID STENOSIS; CEREBRAL ANGIOGRAPHY; CHOLESTEROL, LDL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; LOGISTIC MODELS; MALE; MICHIGAN; RETROSPECTIVE STUDIES; STENTS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 74049139962     PISSN: 10512284     EISSN: 15526569     Source Type: Journal    
DOI: 10.1111/j.1552-6569.2008.00313.x     Document Type: Article

References (23)

1. Schlager O, Exnerr M, Mlekusch W, et al. C-reactive protein predicts future cardiovascular events in patients with carotid stenosis. Stroke 2007 38 : 1263 1268.
2. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998 98 : 731 733.
3. Gröschel K, Ernemann U, Larsen J, et al. Preprocedural C-reactive protein levels predict stroke and death in patients undergoing carotid stenting. Am J Neuroradiol 2007 28 : 1743 1746.
4. Levy EI, Turk AS, Albuquerque FC, et al. Wingspan in-stent restenosis and thrombosis: incidence, clinical presentation and management. Neurosurgery 2007 61 : 644 651.
5. Hong YJ, Jeong MH, Lim SY, et al. Elevated preprocedural high-sensitivity C-reactive protein levels are associated with neointimal hyperplasia and restenosis development after successful coronary artery stenting. Circ J 2005 69 : 1477 1483.
6. Pearson TA, Mensah GA, Alexander RW, et al. Markers for inflammation and the cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003 107 : 499 511.
7. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002 347 : 1557 1565.
8. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005 352 : 20 28.
9. Smith SC Jr., Anderson JL, Cannon RO III., et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: report from the clinical practice discussion group. Circulation 2004 110 : e550 e553.
10. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002 106 : 913 919.
11. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000 102 : 2165 2168.
12. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999 340 : 115 126.
13. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003 108 : 1930 1932.
14. Komatsu R, Ueda M, Naruko T, et al. Neointimal tissue response at sites of coronary stenting in humans. Macroscopic, histological, and immunohistochemical analyses. Circulation 1998 98 : 224 233.
15. Grewe PH, Deneke T, Machraoui A, et al. Acute and chronic tissue response to coronary stent implantation: pathological findings in human specimen. J Am Coll Cardiol 2000 35 : 157 163.
16. Lee CW, Park CB, Kim YH, et al. Incidence and predictors of recurrent restenosis following implantation of drug-eluting stents for in-stent restenosis. Catheter Cardiovasc Interv 2007 69 : 104 108.
17. Roy P, Okabe T, Pinto Slottow TL, et al. Correlates of clinical restenosis following intracoronary implantation of drug-eluting stents. Am J Cardiol 2007 100 : 965 969. (Pubitemid 47368105)
18. Kastrati A, Dibra A, Mehilli J, et al. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 2006 113 : 2293 2300.
19. Gershlick A, De Scheerder I, Chevalier B, et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent. The European evaluation of the palitaxel eluting stent (ELUTES) trial. Circulation 2004 109 : 487 493.
20. Fiorella D, Levy EI, Turk AS, et al. US multicenter experience with the wingspan stent system for the treatment of intracranial atheromatous disease: periprocedural results. Stroke 2007 38 : 881 887.
21. Freitas JM, Zenteno M, Alburto-Murrieta Y, et al. Intracranial arterial stenting for symptomatic stenoses: a Latin American experience. Surg Neurol 2007 68 : 378 386.
22. Gupta R, Al-Ali F, Thomas AJ, et al. Safety, feasibility, and short-term follow-up of drug-eluting stent placement in the intracranial and extracranial circulation. Stroke 2006 37 : 2562 2566.
23. AbuRahma AF, Maxwell D, Eads K, et al. Carotid duplex velocity criteria revisited for the diagnosis of carotid in-stent restenosis. Vascular 2007 15 (3 119 125.